Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells

(2016) Geetika Chakravarty et al.   BIOCHIMIE

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

(2016) Rachid C. Baz et al.   BLOOD

Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer

(2016) R. E. Meyn et al.   CLINICAL CANCER RESEARCH

Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer

(2016) E. J. Hill et al.   CLINICAL CANCER RESEARCH

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

(2016) G P Soriano et al.   LEUKEMIA

Multiple Myeloma: Diagnosis and Treatment

(2016) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

(2016) James M. Wilson et al.   RADIOTHERAPY AND ONCOLOGY

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response

(2016) N Nikesitch et al.   Blood Cancer Journal

A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities

(2015) Gerjan de Bruin et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

(2015) C. Driessen et al.   HAEMATOLOGICA

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

(2015) C. Driessen et al.   HAEMATOLOGICA

Calcium Channel Blocker Verapamil Enhances Reticulum Stress and Death Induced by Proteasome Inhibition in Myeloma Cells

(2015) Silke Meister et al.   NEOPLASIA

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

(2014) S. Bringhen et al.   BLOOD

Quantification of clonal circulating plasma cells in relapsed multiple myeloma

(2014) Wilson I. Gonsalves et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

(2014) Lenka Kubiczkova et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The role of P-glycoprotein in drug resistance in multiple myeloma

(2014) Joseph Abraham et al.   LEUKEMIA & LYMPHOMA

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

What do drug transporters really do?

(2014) Sanjay K. Nigam   NATURE REVIEWS DRUG DISCOVERY

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

(2013) Teresa S. Hawley et al.   AMERICAN JOURNAL OF HEMATOLOGY

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS

(2013) Nan Li et al.   Nature Protocols

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

How I treat plasma cell leukemia

(2012) N. W. C. J. van de Donk et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Interaction of innovative small molecule drugs used for cancer therapy with drug transporters

(2011) K Mandery et al.   BRITISH JOURNAL OF PHARMACOLOGY

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma

(2011) Valdas Peceliunas et al.   LEUKEMIA & LYMPHOMA

The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation

(2011) P. Walter et al.   SCIENCE

Nelfinavir, an HIV-1 Protease Inhibitor, Induces Oxidative Stress–Mediated, Caspase-Independent Apoptosis in Leishmania Amastigotes

(2010) Pranav Kumar et al.   PLoS Neglected Tropical Diseases

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

(2009) D Gutman et al.   LEUKEMIA

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs

(2009) Pär Matsson et al.   PHARMACEUTICAL RESEARCH